Browse studies

Find your next paid study

180 recruiting studies matching your filters

A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer

This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in pat…

Endometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Mucinous Adenocarcinoma+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT05049538

MC230601 Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various her…

Endometrial CarcinomaEndometrial High Grade Endometrioid AdenocarcinomaStage II Endometrial Cancer+2 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT07062016

Phase 1

A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanc…

Ovarian NeoplasmsEndometrial NeoplasmsUterine Cervical Neoplasms+4 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Eli Lilly and CompanyNCT06400472

Phase 1

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and effica…

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Phase 2

A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)

This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back…

Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaRecurrent Endometrial Carcinoma+2 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Jonsson Comprehensive Cancer CenterNCT07634601

Observational

Fasting InTervention for Endometrial Cancer (FIT-ENDO)

The goal of this study is to find out if it is safe for women with endometrial cancer who are going to have surgery to fast (not eat) overnight. Studies have s…

Endometrial Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

University of MiamiNCT07622901

Phase 1

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to…

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more

Phase 2

A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Endometrial Cancer.

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

Endometrial Cancer

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Iovance Biotherapeutics, Inc.NCT06481592

Phase 2

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin

The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, includ…

Ovarian CancerOvarian CarcinomaEndometrial Cancer+5 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT06677190

Phase 3

A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer

The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compa…

Endometrial Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Kara Romano, MDNCT03785288

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

Many clinical trials evaluating cancer treatments require patients to undergo testing for specific molecular markers as part of eligibility screening, typicall…

Neoplasms (Cancer / Tumors)Colorectal NeoplasmsLung Neoplasms+8 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Harvard Medical School (HMS and HSDM)NCT07814872

Phase 3Remote eligible

Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

This is a pragmatic, non-inferiority randomized hybrid decentralized clinical trial. The goal of this study is to determine if one year of maintenance immunoth…

Endometrial AdenocarcinomaMetastatic Endometrial CancerEndometrial Cancer+1 more

Estimated

~$50 – $1,500

Actual pay is set by the research site.

UNC Lineberger Comprehensive Cancer CenterNCT07867002